Primary or metastatic pulmonary or hepatic cancers, or primary pancreatic cancer Lung Neoplasms
Conditions
Interventions
Dynamic tumor tracking volumetric modulated arc therapy (VMAT) and Dynamic SwingArc VMAT
radiotherapy
dynamic tumor tracking
volumetric modulated arc therapy.
Sponsors
Mizowaki Takashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. General eligibility criteria 1) Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 2) Patients with tumors exhibiting respiratory motion of 10 mm or larger. 3) Patients who are inoperable or refuse surgery. 4) Patients who can have gold markers placed near the tumor via bronchoscopic, percutaneous, or endoscopic approaches. 5) Patients aged 18 or older at the time of trial registration. 6) Patients from whom written informed consent can be obtained. 2. Organ-specific eligibility criteria 1) Primary/metastatic pulmonary cancer, primary/metastatic hepatic cancer a) Solitary tumor diameter of 5 cm or less. b) Deemed appropriate for stereotactic body radiotherapy by the attending physician. 2) Primary pancreatic cancer a) Patients without distant metastases. b) Deemed appropriate for concurrent chemoradiotherapy by the attending physician.
Exclusion criteria
Exclusion criteria: 1. General exclusion criteria 1) Presence of severe infections and other serious complications. 2) Medically uncontrolled diabetes, hypertension, renal disease, or liver disease. 3) Presence of scleroderma, mixed connective tissue disease, or active systemic lupus erythematosus (SLE). 4) Women who are pregnant, may be pregnant, or are breastfeeding. 5) Inability to obtain consent for participation in the study. 6) Physician's assessment of a life expectancy of less than three months. 7) Any other condition that the principal investigator or co-investigator deems inappropriate for the study. 2. Organ-specific exclusion criteria 1) Primary/metastatic pulmonary cancer a) Prior history of radiotherapy to the thorax. b) Presence of active interstitial lung disease. 2) Primary/metastatic hepatic cancer a) Prior history of radiotherapy to the upper abdomen. b) Presence of active interstitial lung disease. 3) Primary pancreatic cancer a) Prior history of radiotherapy to the upper abdomen. b) Direct tumor invasion extending to the mucosal surface of the stomach, duodenum, or small intestine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protocol treatment completion rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Dose-volume indices, quality assurance, and 3D tracking accuracy, treatment time, and the incidence of grade 3 or higher acute adverse events (CTCAE v5.0). | — |
Contacts
Public ContactNoriko Kishi
Kyoto University Hospital
Outcome results
None listed